Eli Lilly said enough to convince an FDA advisory panel that its experimental rheumatoid arthritis drug is effective in treating the inflammatory disorder. But on safety, the independent experts were not uniformly persuaded, and they voted to recommend approval only for the lower of two doses. It’s the second time the Lilly drug is up for an approval decision in the past two years.
Of the independent panel’s 15 members, 10 voted against approving Lilly drug baricitinib (Olumiant) at the 4 mg dose based on risks of the pill versus its benefit. But at the 2 mg dose, the vote was… Read more »
UNDERWRITERS AND PARTNERS